Cryosite Ltd (CTE) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.387x

Based on the latest financial reports, Cryosite Ltd (CTE) has a cash flow conversion efficiency ratio of 0.387x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$924.00K ≈ $653.79K USD) by net assets (AU$2.39 Million ≈ $1.69 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cryosite Ltd - Cash Flow Conversion Efficiency Trend (2001–2025)

This chart illustrates how Cryosite Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CTE liabilities breakdown for a breakdown of total debt and financial obligations.

Cryosite Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cryosite Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Waystream Holding AB (publ)
ST:WAYS
0.161x
Duro Felguera
MC:MDF
0.035x
Home Capital Rentals SOCIMI S.A.
MC:YHCR
0.020x
Artea SA
PA:ARTE
-0.078x
Aviation Links Ltd
TA:AVIA
0.078x
Dacome International Ltd
TWO:9960
0.041x
Woojin Plaimm
KO:049800
0.110x
Dedicare AB (publ)
ST:DEDI
-0.118x

Annual Cash Flow Conversion Efficiency for Cryosite Ltd (2001–2025)

The table below shows the annual cash flow conversion efficiency of Cryosite Ltd from 2001 to 2025. For the full company profile with market capitalisation and key ratios, see CTE market cap overview.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$2.39 Million
≈ $1.69 Million
AU$2.06 Million
≈ $1.46 Million
0.864x -54.36%
2024-06-30 AU$1.45 Million
≈ $1.03 Million
AU$2.74 Million
≈ $1.94 Million
1.893x +274.03%
2023-06-30 AU$2.78 Million
≈ $1.97 Million
AU$1.41 Million
≈ $996.25K
0.506x -62.25%
2022-06-30 AU$1.86 Million
≈ $1.32 Million
AU$2.49 Million
≈ $1.77 Million
1.341x +130.27%
2021-06-30 AU$819.23K
≈ $579.65K
AU$476.96K
≈ $337.48K
0.582x -93.10%
2020-06-30 AU$154.88K
≈ $109.58K
AU$1.31 Million
≈ $924.35K
8.435x +2135.42%
2019-06-30 AU$-1.72 Million
≈ $-1.21 Million
AU$-647.54K
≈ $-458.17K
0.377x +379.99%
2018-06-30 AU$1.94 Million
≈ $1.38 Million
AU$-261.91K
≈ $-185.32K
-0.135x -126.08%
2017-06-30 AU$3.15 Million
≈ $2.23 Million
AU$1.63 Million
≈ $1.15 Million
0.517x +267.77%
2016-06-30 AU$3.38 Million
≈ $2.39 Million
AU$474.61K
≈ $335.82K
0.140x -64.86%
2015-06-30 AU$3.54 Million
≈ $2.51 Million
AU$1.42 Million
≈ $1.00 Million
0.400x +54.74%
2014-06-30 AU$6.14 Million
≈ $4.34 Million
AU$1.58 Million
≈ $1.12 Million
0.258x -16.57%
2013-06-30 AU$6.26 Million
≈ $4.43 Million
AU$1.94 Million
≈ $1.37 Million
0.310x -9.74%
2012-06-30 AU$5.48 Million
≈ $3.88 Million
AU$1.88 Million
≈ $1.33 Million
0.343x +13.39%
2011-06-30 AU$4.69 Million
≈ $3.32 Million
AU$1.42 Million
≈ $1.00 Million
0.303x +34.76%
2010-06-30 AU$4.35 Million
≈ $3.08 Million
AU$977.66K
≈ $691.75K
0.225x +37.27%
2009-06-30 AU$4.34 Million
≈ $3.07 Million
AU$709.86K
≈ $502.27K
0.164x -20.44%
2008-06-30 AU$4.32 Million
≈ $3.06 Million
AU$888.27K
≈ $628.51K
0.206x +10.08%
2007-06-30 AU$3.74 Million
≈ $2.64 Million
AU$697.65K
≈ $493.63K
0.187x +358.76%
2006-06-30 AU$2.81 Million
≈ $1.99 Million
AU$-203.02K
≈ $-143.65K
-0.072x +10.55%
2005-06-30 AU$2.48 Million
≈ $1.75 Million
AU$-199.90K
≈ $-141.44K
-0.081x +66.81%
2004-06-30 AU$3.04 Million
≈ $2.15 Million
AU$-738.72K
≈ $-522.69K
-0.243x +20.88%
2002-06-30 AU$3.89 Million
≈ $2.75 Million
AU$-1.20 Million
≈ $-845.61K
-0.307x -27.31%
2001-06-30 AU$3.87 Million
≈ $2.74 Million
AU$-933.52K
≈ $-660.52K
-0.241x --

About Cryosite Ltd

AU:CTE Australia Diagnostics & Research
Market Cap
$36.95 Million
AU$52.23 Million AUD
Market Cap Rank
#22967 Global
#876 in Australia
Share Price
AU$1.07
Change (1 day)
-4.46%
52-Week Range
AU$0.66 - AU$1.30
All Time High
AU$1.30
About

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial … Read more